Severe Childhood Psoriasis: 3-Year-Old, 12 kg

Key Challenge: Age/Weight Constraints

Step 1: Topical Therapy (First-Line for All Severity Levels to Start)

Topical Corticosteroids

• Low-to-mid potency preferred in young children (avoid high-potency on large BSA, face, flexures)
• Examples: hydrocortisone 1–2.5% (face/flexures), triamcinolone 0.025–0.1% (body)
• Risk: HPA suppression, skin atrophy — greatest in infants/toddlers due to high SA:weight ratio
• Use intermittently (weekdays on / weekends off, or weekend-only maintenance)

Vitamin D Analogues

• Calcipotriol (calcipotriene) 0.005% cream/ointment — first-line steroid-sparing agent
• Can be combined with betamethasone dipropionate (Dovobet/Enstilar) but combination products lack pediatric safety data < 6 years
• Hypercalcemia risk with excessive application — keep to < 50 g/week total in children (proportionally less at 12 kg)

Topical Calcineurin Inhibitors (TCIs)

• Tacrolimus 0.03% ointment or pimecrolimus 1% cream — approved from age 2
• Particularly useful for face, flexures, and intertriginous areas where steroids carry higher risk
• Good for scalp, periorbital, genital psoriasis

Coal Tar Preparations

• Effective, safe; useful for scalp psoriasis
• Less cosmetically acceptable (odor, staining)

Emollients

• Essential adjunct; reduce scaling, pruritus, and barrier dysfunction
• Apply liberally and frequently — key in pediatric patients

Step 2: Phototherapy (If Topicals Inadequate)

• Narrowband UVB (NB-UVB) is the preferred phototherapy modality in children
• Safe from infancy when carefully administered; no age cutoff
• Practical challenges at age 3: requires cooperation, standing still in a booth — may be feasible with parental support or home units
• PUVA (psoralen + UVA) avoided in young children due to need for oral psoralen, eye protection issues, and long-term skin cancer risk
• Excimer laser (308 nm) useful for localized plaques

Step 3: Systemic Non-Biologic Therapy

Methotrexate

• Most widely used systemic agent in pediatric psoriasis, including very young children
• Weight-based dosing: 0.2–0.4 mg/kg/week PO or SC (max ~15 mg/week initially)
  • At 12 kg: starting dose ~2.5–4.8 mg/week
• Folate supplementation (1 mg/day) essential to reduce mucositis/hematologic side effects
• Monitor: CBC, LFTs every 4–8 weeks
• Contraindicated in active infections, liver disease, immunodeficiency
• Off-label in this age group but well-established pediatric dermatology practice

Acitretin (Retinoid)

• Particularly effective in pustular or erythrodermic psoriasis
• Dose: 0.5–1 mg/kg/day
• Concerns: teratogenicity (relevant for female patients even at this age due to drug's long half-life), mucocutaneous dryness, hyperlipidemia
• Not typically first-choice for plaque psoriasis in toddlers

Cyclosporine

• Useful for acute, severe flares requiring rapid control
• Dose: 2.5–5 mg/kg/day
• Short courses only (≤ 3–4 months); nephrotoxicity, hypertension with prolonged use
• Monitor renal function and blood pressure closely

Step 4: Biologic Therapy (Off-Label in < 6 Years)

Etanercept (TNF-α inhibitor)

• Most studied biologic in young children with psoriasis (off-label < 6 yrs)
• Evidence from juvenile idiopathic arthritis down to age 2 at 0.8 mg/kg/week SC (max 50 mg/week)
• Some pediatric dermatology centers extrapolate this dosing to severe psoriasis < 6 yrs
• At 12 kg: approximately 10 mg SC once weekly

Ustekinumab (IL-12/23 inhibitor)

• Approved ≥ 6 years; case reports of use in younger children with severe psoriasis
• Weight-based: < 60 kg → 0.75 mg/kg SC at weeks 0, 4, then every 12 weeks

Secukinumab (IL-17A inhibitor)

• Approved ≥ 6 years for plaque psoriasis; however, approved for juvenile PsA from age 2 (≥ 15 kg) at 75 mg SC
• If psoriatic arthritis is a component, this creates a pathway to earlier use
• At 12 kg: below the weight threshold even for JIA indication (15 kg cutoff)

Emerging / Near-Future Option

Roflumilast Cream 0.3% (Zoryve)

• Topical PDE4 inhibitor, currently approved from age 6 for plaque psoriasis
• sNDA filed November 2025; FDA PDUFA date: June 29, 2026 for ages 2–5
• Supported by MUSE study and long-term open-label data in the 2–5 age range
• This patient (age 3) would fall within the proposed new indication if approved
• Non-steroidal, once-daily application — would represent a significant option for this age group

Practical Management Algorithm for This Patient

SEVERE psoriasis, 3 yrs, 12 kg
├── Optimize topicals:
│   ├── Low/mid-potency TCS (pulse dosing)
│   ├── Calcipotriol cream
│   └── TCIs for sensitive areas
├── Add NB-UVB phototherapy if feasible
├── If inadequate after 4–8 weeks:
│   └── Methotrexate 2.5–4.8 mg/week + folic acid
├── If inadequate / severe flare:
│   └── Short-course cyclosporine (bridge)
└── Refractory / severe: Specialist referral
    └── Off-label biologic (etanercept first choice)
        Watch for roflumilast 0.3% cream approval June 2026

Special Considerations

Summary

⚠️ Clinical note: All systemic and biologic use in children < 6 years for plaque psoriasis is off-label in most jurisdictions. Decisions should be made by or with a pediatric dermatologist with appropriate informed consent, monitoring protocols, and documentation.